Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting - Scicali, Roberto; Di Pino, Antonino; Ferrara, Viviana; Rabuazzo, Agata Maria; Purrello, Francesco; Piro, Salvatore (Acta diabetologica, 2021)
Keywords: Aged; Anticholesteremic Agents - administration & dosage; Anticholesteremic Agents - adverse effects; Anticholesteremic Agents - pharmacology; Arteriosclerosis; Biochemical analysis; Blood Flow Velocity - drug effects; Cholesterol; Cholesterol, HDL - blood; Cohort Studies; Diabetes; Drug Therapy, Combination; Ezetimibe - administration & dosage; Ezetimibe - adverse effects; Ezetimibe - pharmacology; Female; High density lipoprotein; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage; Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects; Hypercholesterolemia; Hyperlipoproteinemia Type II - blood; Hyperlipoproteinemia Type II - drug therapy; Hyperlipoproteinemia Type II - physiopathology; Inflammation; Internal Medicine; Italy; Leukocyte Count; Leukocytes (neutrophilic); Lipid Metabolism - drug effects; Low density lipoprotein; Lymphocytes; Male; Medicine; Medicine & Public Health; Metabolic Diseases; Middle Aged; Monocytes; Monocytes - drug effects; Monocytes - pathology; Neutrophils; Original; Original Article; PCSK9 Inhibitors; Prospective Studies; Pulse Wave Analysis; Statins; Velocity; Italy; Pulse wave velocity; PCSK9 inhibitors; Innate immunity; Inflammatory profile; Familial hypercholesterolemia; Cardiovascular risk